Glycogen Synthase Kinase 3: A Target for Novel Mood Disorder Treatments

Glycogen Synthase Kinase 3 (GSK-3) and Its Inhibitors: Drug Discovery and Development

Volumn , Issue , 2006, Pages 125-154

  Gould, Todd D ^a   Manji, Husseini K ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Lithium molecular effects; Novel mood disorder treatment target; Thymoleptic medications on GSK 3 mediated signaling

Indexed keywords

EID: 84863003621     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470052174.ch7     Document Type: Chapter

References (159)

1. Evans D.L., Charney D.S. (2003). Mood disorders and medical illness: A major public health problem. Biol. Psychiat., 54, 177-180.
2. Michaud C.M., Murray C.J., Bloom B.R. (2001). Burden of disease-Implications for future research. JAMA, 285, 535-539.
3. Potash J.B., DePaulo J.R. Jr. (2000). Searching high and low: A review of the genetics of bipolar disorder. Bipolar Disord., 2, 8-26.
4. Craddock N., Jones I. (1999). Genetics of bipolar disorder. J. Med. Genet., 36, 585-594.
5. Sullivan P.F., Neale M.C., Kendler K.S. (2000). Genetic epidemiology of major depression: Review and meta-analysis. Am. J. Psychiat., 157, 1552-1562.
6. Fava M., Kendler K.S. (2000). Major depressive disorder. Neuron, 28, 335-341.
7. Cardno A.G., Marshall E.J., Coid B., Macdonald A.M., Ribchester T.R., Davies N.J., Venturi P., Jones L.A., Lewis S.W., Sham P.C., Gottesman I.I., Farmer A.E., McGuffin P., Reveley A.M., Murray R.M. (1999). Heritability estimates for psychotic disorders: The Maudsley twin psychosis series. Arch. Gen. Psychiat., 56, 162-168.
8. Kendler K.S., Pedersen N.L., Neale M.C., Mathe A.A. (1995). A pilot Swedish twin study of affective illness including hospital-and population-ascertained subsamples: Results of model fitting. Behav. Genet., 25, 217-232.
9. Poulsen P., Kyvik K.O., Vaag A., Beck-Nielsen H. (1999). Heritability of type II (non-insulin-dependent) diabetes mellitus and abnormal glucose tolerance-A population-based twin study. Diabetologia, 42, 139-145.
10. Manji H.K., Gottesman I.I., Gould T.D. (2003). Signal transduction and genesto-behaviors pathways in psychiatric diseases. Sci. STKE, 2003, 49.
11. Petronis A. (2003). Epigenetics and bipolar disorder: New opportunities and challenges. Am. J. Med. Genet., 123C, 65-75.
12. Lenox R.H., Gould T.D., Manji H.K. (2002). Endophenotypes in bipolar disorder. Am. J. Med. Genet., 114, 391-406.
13. Manji H.K., Moore G.J., Rajkowska G., Chen G. (2000). Neuroplasticity and cellular resilience in mood disorders. Mol. Psychiat., 5, 578-593.
14. Schou M. (2001). Lithium treatment at 52. J. Affect. Disord., 67, 21-32.
15. Tohen M., Vieta E., Calabrese J., Ketter T.A., Sachs G., Bowden C., Mitchell P.B., Centorrino F., Risser R., Baker R.W., Evans A.R., Beymer K., Dube S., Tollefson G.D., Breier A. (2003). Efficacy of olanzapine and olanzapinefluoxetine combination in the treatment of bipolar I depression. Arch. Gen. Psychiatry., 60, 1079-1088.
16. Bowden C.L. (2005). Treatment options for bipolar depression. J. Clin. Psychiat., 66(suppl. 1), 3-6.
17. Walsh B.T., Seidman S.N., Sysko R., Gould M. (2002). Placebo response in studies of major depression: Variable, substantial, and growing. JAMA, 287, 1840-1847.
18. Gould T.D., Quiroz J.A., Singh J., Zarate C.A., Manji H.K. (2004). Emerging experimental therapeutics for bipolar disorder: Insights from the molecular and cellular actions of current mood stabilizers. Mol. Psychiat., 9, 734-755.
19. Quiroz J.A., Singh J., Gould T.D., Denicoff K.D., Zarate C.A., Manji H.K. (2004). Emerging experimental therapeutics for bipolar disorder: Clues from the molecular pathophysiology. Mol. Psychiat., 9, 756-776.
20. Picchini A.M., Manji H.K., Gould T.D. (2004). GSK-3 and neurotrophic signaling: Novel targets underlying the pathophysiology and treatment of mood disorders?. Drug Disc. Today: Dis. Mech., 1, 419-428.
21. Cade J.F.J. (1949). Lithium salts in the treatment of psychotic excitement. Med. J. Austr., 2, 349-352.
22. Souza F.G., Goodwin G.M. (1991). Lithium treatment and prophylaxis in unipolar depression: A meta-analysis. Br. J. Psychiat., 158, 666-675.
23. Bauer M.S., Mitchner L. (2004). What is a "mood stabilizer"? An evidencebased response. Am. J. Psychiat., 161, 3-18.
24. Heninger G.R., Charney D.S., Sternberg D.E. (1983). Lithium carbonate augmentation of antidepressant treatment: An effective prescription for treatmentrefractory depression. Arch. Gen. Psychiat., 40, 1335-1342.
25. Bauer M., Forsthoff A., Baethge C., Adli M., Berghofer A., Dopfmer S., Bschor T. (2003). Lithium augmentation therapy in refractory depression-Update 2002. Eur. Arch. Psychiat. Clin. Neurosci., 253, 132-139.
26. Muller-Oerlinghausen B. (2001). Arguments for the specificity of the antisuicidal effect of lithium. Eur. Arch. Psychiat. Clin. Neurosci., 251 (suppl. 2), II72-II75.
27. Baldessarini R.J., Tondo L., Hennen J. (2001). Treating the suicidal patient with bipolar disorder. Reducing suicide risk with lithium. An. NY Acad. Sci., 932, 24-38; discussion 39-43.
28. Goodwin F.K., Fireman B., Simon G.E., Hunkeler E.M., Lee J., Revicki D. (2003). Suicide risk in bipolar disorder during treatment with lithium and divalproex. JAMA, 290, 1467-1473.
29. Phiel C.J., Klein P.S. (2001). Molecular targets of lithium action. An. Rev. Pharmacol. Toxicol., 41, 789-813.
30. Jope R.S. (1999). Anti-bipolar therapy: Mechanism of action of lithium. Mol. Psychiat., 4, 117-128.
31. Gould T.D., Chen G., Manji H.K. (2002). Mood stabilizer psychopharmacology. Clin. Neurosci. Res., 2, 193-212.
32. Belmaker R.H. (2004). Bipolar disorder. N. Engl. J. Med., 351, 476-486.
33. Belmaker R.H., Kofman O. (1990). Lithium research: State of the art. Biol. Psychiat., 27, 1279-1281.
34. York J.D., Ponder J.W., Majerus P.W. (1995). Definition of a metal-dependent/Li(+)-inhibited phosphomonoesterase protein family based upon a conserved three-dimensional core structure. Proc. Natl. Acad. Sci. USA, 92, 5149-5153.
35. Nordenberg J., Kaplansky M., Beery E., Klein S., Beitner R. (1982). Effects of lithium on the activities of phosphofructokinase and phosphoglucomutase and on glucose-1,6-diphosphate levels in rat muscles, brain and liver. Biochem. Pharmacol., 31, 1025-1031.
36. Rhyu G.I., Ray W.J. Jr., Markley J.L. (1984). Enzyme-bound intermediates in the conversion of glucose 1-phosphate to glucose 6-phosphate by phosphoglucomutase: Phosphorus NMR studies. Biochemistry, 23, 252-260.
37. Ray W.J. Jr., Szymanki E.S., Ng L. (1978). The binding of lithium and of anionic metabolites to phosphoglucomutase. Biochim. Biophys. Acta, 522, 434-442.
38. Masuda C.A., Xavier M.A., Mattos K.A., Galina A., Montero-Lomeli M. (2001). Phosphoglucomutase is an in vivo lithium target in yeast. J. Biol. Chem., 276, 37794-37801.
39. Klein P.S., Melton D.A. (1996). A molecular mechanism for the effect of lithium on development. Proc. Natl. Acad. Sci. USA, 93, 8455-8459.
40. Stambolic V., Ruel L., Woodgett J.R. (1996). Lithium inhibits glycogen synthase kinase-3 activity and mimics wingless signalling in intact cells. Curr. Biol., 6, 1664-1668.
41. Atack J.R. (2000). Lithium, phosphatidylinositol signaling, and bipolar disorder. In Manji H.K., Bowden C.L., Belmaker R.H., eds., Bipolar Medications: Mechanism of Action. Washington, DC: American Psychiatric Press, 1-30.
42. Majerus P.W. (1992). Inositol phosphate biochemistry. An. Rev. Biochem., 61, 225-250.
43. Naccarato W.F., Ray R.E., Wells W.W. (1974). Biosynthesis of myo-inositol in rat mammary gland. Isolation and properties of the enzymes. Arch. Biochem. Biophys., 164, 194-201.
44. Hallcher L.M., Sherman W.R. (1980). The effects of lithium ion and other agents on the activity of myo-inositol-1-phosphatase from bovine brain. J. Biol. Chem., 255, 10896-10901.
45. Berridge M.J., Downes C.P., Hanley M.R. (1989). Neural and developmental actions of lithium: A unifying hypothesis. Cell, 59, 411-419.
46. Allison J.H., Stewart M.A. (1971). Reduced brain inositol in lithium-treated rats. Nat. New Biol., 233, 267-268.
47. Gould T.D., Manji H.K. (2002). Signaling networks in the pathophysiology and treatment of mood disorders. J. Psychosom. Res., 53, 687-697.
48. Moore G.J., Bebchuk J.M., Parrish J.K., Faulk M.W., Arfken C.L., Strahl-Bevacqua J., Manji H.K. (1999). Temporal dissociation between lithiuminduced changes in frontal lobe myo-inositol and clinical response in manic-depressive illness. Am. J. Psychiat., 156, 1902-1908.
49. Manji H.K., Lenox R.H. (1999). Ziskind-Somerfeld Research Award. Protein kinase C signaling in the brain: Molecular transduction of mood stabilization in the treatment of manic-depressive illness. Biol. Psychiat., 46, 1328-1351.
50. Atack J.R. (1997). Inositol monophosphatase inhibitors-lithium mimetics? Med. Res. Rev., 17, 215-224.
51. Atack J.R., Cook S.M., Watt A.P., Fletcher S.R., Ragan C.I. (1993). In vitro and in vivo inhibition of inositol monophosphatase by the bisphosphonate L-690,330. J. Neurochem., 60, 652-658.
52. Atack J.R., Prior A.M., Fletcher S.R., Quirk K., McKernan R., Ragan C.I. (1994). Effects of L-690,488, a prodrug of the bisphosphonate inositol monophosphatase inhibitor L-690,330, on phosphatidylinositol cycle markers. J. Pharmacol. Exp. Ther., 270, 70-76.
53. Pollack S.J., Atack J.R., Knowles M.R., McAllister G., Ragan C.I., Baker R., Fletcher S.R., Iversen L.L., Broughton H.B. (1994). Mechanism of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. USA, 91, 5766-5770.
54. Bone R., Springer J.P., Atack J.R. (1992). Structure of inositol monophosphatase, the putative target of lithium therapy. Proc. Natl. Acad. Sci. USA, 89, 10031-10035.
55. Bebchuk J.M., Arfken C.L., Dolan-Manji S., Murphy J., Hasanat K., Manji H.K. (2000). A preliminary investigation of a protein kinase C inhibitor in the treatment of acute mania. Arch. Gen. Psychiat., 57, 95-97.
56. Grimes C.A., Jope R.S. (2001). The multifaceted roles of glycogen synthase kinase 3beta in cellular signaling. Prog. Neurobiol., 65, 391-426.
57. Woodgett J.R. (2001). Judging a protein by more than its name: GSK-3. Sci. STKE, RE12.
58. Frame S., Cohen P. (2001). GSK-3 takes centre stage more than 20 years after its discovery. Biochem. J., 359, 1-16.
59. Logan C.Y., Nusse R. (2004). The Wnt signaling pathway in development and disease. An. Rev. Cell. Dev. Biol., 20, 781-810.
60. Eldar-Finkelman H., Ilouz R. (2003). Challenges and opportunities with glycogen synthase kinase-3 inhibitors for insulin resistance and type 2 diabetes treatment. Expert Opin. Investig. Drugs, 12, 1511-1519.
61. Huang H.C., Klein P.S. (2004). The Frizzled family: Receptors for multiple signal transduction pathways. Genome Biol., 5, 234.
62. Jope R.S., Johnson G.V. (2004). The glamour and gloom of glycogen synthase kinase-3. Trends Biochem. Sci., 29, 95-102.
63. Gould T.D., Manji H.K. (2002). The Wnt signaling pathway in bipolar disorder. Neuroscientist, 8, 497-511.
64. Ryves W.J., Harwood A.J. (2001). Lithium inhibits glycogen synthase kinase-3 by competition for magnesium. Biochem. Biophys. Res. Commun., 280, 720-725.
65. Gurvich N., Klein P.S. (2002). Lithium and valproic acid: Parallels and contrasts in diverse signaling contexts. Pharmacol. Ther., 96, 45-66.
66. Ryves W.J., Dajani R., Pearl L., Harwood A.J. (2002). Glycogen synthase kinase-3 inhibition by lithium and beryllium suggests the presence of two magnesium binding sites. Biochem. Biophys. Res. Commun., 290, 967-972.
67. Ilouz R., Kaidanovich O., Gurwitz D., Eldar-Finkelman H. (2002). Inhibition of glycogen synthase kinase-3beta by bivalent zinc ions: Insight into the insulin-mimetic action of zinc. Biochem. Biophys. Res. Commun., 295, 102-106.
68. Gee J.B. 2nd Corbett R.J., Perlman J.M., Laptook A.R. (2001). Hypermagnesemia does not increase brain intracellular magnesium in newborn swine. Pediatr. Neurol., 25, 304-308.
69. Gotoh H., Kajikawa M., Kato H., Suto K. (1999). Intracellular Mg2+ surge follows Ca2+ increase during depolarization in cultured neurons. Brain Res., 828, 163-168.
70. Li-Smerin Y., Levitan E.S., Johnson J.W. (2001). Free intracellular Mg(2+) concentration and inhibition of NMDA responses in cultured rat neurons. J. Physiol., 533, 729-743.
71. Brocard J.B., Rajdev S., Reynolds I.J. (1993). Glutamate-induced increases in intracellular free Mg2+ in cultured cortical neurons. Neuron, 11, 751-757.
72. Amari L., Layden B., Nikolakopoulos J., Rong Q., Mota de Freitas D., Baltazar G., Castro M.M., Geraldes C.F. (1999). Competition between Li+ and Mg2+ in neuroblastoma SH-SY5Y cells: A fluorescence and 31P NMR study. Biophys. J., 76, 2934-2942.
73. Chalecka-Franaszek E., Chuang D.M. (1999). Lithium activates the serine/threonine kinase Akt-1 and suppresses glutamate-induced inhibition of Akt-1 activity in neurons. Proc. Natl. Acad. Sci. USA, 96, 8745-8750.
74. De Sarno P., Li X., Jope R.S. (2002). Regulation of Akt and glycogen synthase kinase-3beta phosphorylation by sodium valproate and lithium. Neuropharmacology, 43, 1158-1164.
75. Jope R.S. (2003). Lithium and GSK-3: One inhibitor, two inhibitory actions, multiple outcomes. Trends. Pharmacol. Sci., 24, 441-443.
76. Zhang F., Phiel C.J., Spece L., Gurvich N., Klein P.S. (2003). Inhibitory phosphorylation of glycogen synthase kinase-3 (GSK-3) in response to lithium: Evidence for autoregulation of GSK-3. J. Biol. Chem., 278, 33067-33077.
77. Kirshenboim N., Plotkin B., Shlomo S.B., Kaidanovich-Beilin O., Eldar-Finkelman H. (2004). Lithium-mediated phosphorylation of glycogen synthase kinase-3b involves PI3 kinase-dependent activation of protein kinase C-alpha. J. Mol. Neurosci., 24, 237-246.
78. Munoz-Montano J.R., Moreno F.J., Avila J., Díaz-Nido J. (1997). Lithium inhibits Alzheimer's disease-like Tau protein phosphorylation in neurons. FEBS. Lett., 411, 183-188.
79. De Ferrari G.V., Chacon M.A., Barria M.I., Garrido J.L., Godoy J.A., Olivares G., Reyes A.E., Alvarez A., Bronfman M., Inestrosa N.C. (2003). Activation of Wnt signaling rescues neurodegeneration and behavioral impairments induced by beta-amyloid fibrils. Mol. Psychiat., 8, 195-208.
80. O'Brien W.T., Harper A.D., Jove F., Woodgett J.R., Maretto S., Piccolo S., Klein P.S. (2004). Glycogen synthase kinase-3beta haploinsufficiency mimics the behavioral and molecular effects of lithium. J. Neurosci., 24, 6791-6798.
81. Gould T.D., Chen G., Manji H.K. (2004). In vivo evidence in the brain for lithium inhibition of glycogen synthase kinase-3. Neuropsychopharmacology, 29, 32-38.
82. Gould T.D., Picchini A.M., Einat H., Manji H.K. (in press). Targeting glycogen synthase kinase-3 in the CNS: implications for the development of new treatments for mood disorders. Curr. Drug Targets.
83. Emrich H.M., von Zerssen D., Kissling W., Moller H.J., Windorfer A. (1980). Effect of sodium valproate on mania: The GABA-hypothesis of affective disorders. Arch. Psychiatr. Nervenkr., 229, 1-16.
84. Lambert P.A., Venaud G. (1987). Use of valpromide in psychiatric therapeutics. Encephale, 13, 367-373.
85. Bowden C.L., Brugger A.M., Swann A.C., Calabrese J.R., Janicak P.G., Petty F., Dilsaver S.C., Davis J.M., Rush A.J., Small J.G., et al. (1994). Efficacy of divalproex vs lithium and placebo in the treatment of mania: The Depakote Mania Study Group. JAMA, 271, 918-924.
86. Pope H.G. Jr., McElroy S.L., Keck P.E. Jr., Hudson J.I. (1991). Valproate in the treatment of acute mania: A placebo-controlled study. Arch. Gen. Psychiat., 48, 62-68.
87. Lemperiere T. (2001). Brief history of the development of valproate in bipolar disorders. Encephale, 27, 365-372.
88. Lambert P.A., Venaud G. (1992). Comparative study of valpromide versus lithium in the treatment of affective disorders. Nervure, 5, 57-65.
89. Bowden C.L., Calabrese J.R., McElroy S.L., Gyulai L., Wassef A., Petty F., Pope H.G. Jr., Chou J.C., Keck P.E. Jr., Rhodes L.J., Swann A.C., Hirschfeld R.M., Wozniak P.J. (2000). A randomized, placebo-controlled 12-month trial of divalproex and lithium in treatment of outpatients with bipolar I disorder: Divalproex Maintenance Study Group. Arch. Gen. Psychiat., 57, 481-489.
90. Chen G., Huang L.D., Jiang Y.M., Manji H.K. (1999). The mood-stabilizing agent valproate inhibits the activity of glycogen synthase kinase-3. J. Neurochem, 72, 1327-1330.
91. Grimes A.C., Jope R.S. (2001). CREB DNA binding activity is inhibited by glycogen synthase kinase-3beta and facilitated by lithium. J. Neurochem, 78, 1219-1232.
92. Werstuck G.H., Kim A.J., Brenstrum T., Ohnmacht S.A., Panna E., Capretta A. (2004). Examining the correlations between GSK-3 inhibitory properties and anti-convulsant efficacy of valproate and valproate-related compounds. Bioorg. Med. Chem. Lett., 14, 5465-5467.
93. Kim A.J., Shi Y., Austin R.C., Werstuck G.H. (2005). Valproate protects cells from ER stress-induced lipid accumulation and apoptosis by inhibiting glycogen synthase kinase-3. J. Cell. Sci., 118, 89-99.
94. Phiel C.J., Zhang F., Huang E.Y., Guenther M.G., Lazar M.A., Klein P.S. (2001). Histone deacetylase is a direct target of valproic acid, a potent anticonvulsant, mood stabilizer, and teratogen. J. Biol. Chem., 276, 36734-36741.
95. Williams R.S., Cheng L., Mudge A.W., Harwood A.J. (2002). A common mechanism of action for three mood-stabilizing drugs. Nature, 417, 292-295.
96. Williams R.S., Eickholt B.J., Towers G., Ryves W.J., Eikel D., Adley K., Ylinen L., Chadborn N., Harwood A., Nau H. (2005). Effects of valproic acid derivatives on inositol trisphosphate depletion, teratogenicity, GSK-3{beta} inhibition and viral replication-A screening approach for new bipolar disorder drugs based on the valproic acid core structure. Mol. Pharmacol., 67, 1426-1433.
97. Jonathan Ryves W., Dalton E.C., Harwood A.J., Williams R.S. (2005). GSK-3 activity in neocortical cells is inhibited by lithium but not carbamazepine or valproic acid. Bipolar Disord., 7, 260-265.
98. Hall A.C., Brennan A., Goold R.G., Cleverley K., Lucas F.R., Gordon-Weeks P.R., Salinas P.C. (2002). Valproate regulates GSK-3-mediated axonal remodeling and synapsin I clustering in developing neurons. Mol. Cell. Neurosci., 20, 257-270.
99. Roh M.S., Eom T.Y., Zmijewska A.A., De Sarno P., Roth K.A., Jope R.S. (2005). Hypoxia activates glycogen synthase kinase-3 in mouse brain in vivo: protection by mood stabilizers and imipramine. Biol. Psychiat., 57, 278-286.
100. Li X., Bijur G.N., Jope R.S. (2002). Glycogen synthase kinase 3-beta, mood stabilizers, and neuroprotection. Bipolar Disord., 4, 137-144.
101. Li X., Zhu W., Roh M.S., Friedman A.B., Rosborough K., Jope R.S. (2004). In vivo regulation of glycogen synthase kinase-3beta (GSK3beta) by serotonergic activity in mouse brain. Neuropsychopharmacology, 29, 1426-1431.
102. Mukherjee S., Sackeim H.A., Schnur D.B. (1994). Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am. J. Psychiat., 151, 169-176.
103. Roh M.S., Kang U.G., Shin S.Y., Lee Y.H., Jung H.Y., Juhnn Y.S., Kim Y.S. (2003). Biphasic changes in the Ser-9 phosphorylation of glycogen synthase kinase-3beta after electroconvulsive shock in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiat., 27, 1-5.
104. Kang U.G., Roh M.S., Jung J.R., Shin S.Y., Lee Y.H., Park J.B., Kim Y.S. (2004). Activation of protein kinase B (Akt) signaling after electroconvulsive shock in the rat hippocampus. Prog. Neuropsychopharmacol. Biol. Psychiat., 28, 41-44.
105. Madsen T.M., Newton S.S., Eaton M.E., Russell D.S., Duman R.S. (2003). Chronic electroconvulsive seizure up-regulates beta-catenin expression in rat hippocampus: Role in adult neurogenesis. Biol. Psychiat., 54, 1006-1014.
106. Malberg J.E., Eisch A.J., Nestler E.J., Duman R.S. (2000). Chronic antidepressant treatment increases neurogenesis in adult rat hippocampus. J. Neurosci., 20, 9104-9110.
107. Kang U.G., Seo M.S., Roh M.S., Kim Y., Yoon S.C., Kim Y.S. (2004). The effects of clozapine on the GSK-3-mediated signaling pathway. FEBS Lett., 560, 115-119.
108. Emamian E.S., Hall D., Birnbaum M.J., Karayiorgou M., Gogos J.A. (2004). Convergent evidence for impaired AKT1-GSK3beta signaling in schizophrenia. Nat. Genet., 36, 131-137.
109. Alimohamad H., Rajakumar N., Seah Y.H., Rushlow W. (2005). Antipsychotics alter the protein expression levels of beta-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiat., 57, 533-542.
110. Payne J.L. (2003). The role of estrogen in mood disorders in women. Int. Rev. Psychiat., 15, 280-290.
111. Bloch M., Daly R.C., Rubinow D.R. (2003). Endocrine factors in the etiology of postpartum depression. Compr. Psychiat., 44, 234-246.
112. Lee S.J., McEwen B.S. (2001). Neurotrophic and neuroprotective actions of estrogens and their therapeutic implications. An. Rev. Pharmacol. Toxicol., 41, 569-591.
113. Ramirez V.D., Kipp J.L., Joe I. (2001). Estradiol, in the CNS, targets several physiologically relevant membrane-associated proteins. Brain. Res. Rev., 37, 141-152.
114. Cardona-Gomez P., Perez M., Avila J., Garcia-Segura L.M., Wandosell F. (2004). Estradiol inhibits GSK-3 and regulates interaction of estrogen receptors, GSK-3, and beta-catenin in the hippocampus. Mol. Cell. Neurosci., 25, 363-373.
115. Kouzmenko A.P., Takeyama K., Ito S., Furutani T., Sawatsubashi S., Maki A., Suzuki E., Kawasaki Y., Akiyama T., Tabata T., Kato S. (2004). Wnt/betacatenin and estrogen signaling converge in vivo. J. Biol. Chem., 279, 40255-40258.
116. Gunin A.G., Emelianov V.U., Mironkin I.U., Morozov M.P., Tolmachev A.S. (2004). Lithium treatment enhances estradiol-induced proliferation and hyperplasia formation in the uterus of mice. Eur. J. Obstet. Gynecol. Reprod. Biol., 114, 83-91.
117. Medunjanin S., Hermani A., De Servi B., Grisouard J., Rincke G., Mayer D. (in press). Glycogen synthase kinase-3 interacts with and phosphorylates estrogen receptor-alpha and is involved in the regulation of receptor activity. J. Biol. Chem.
118. Shaw P.C., Davies A.F., Lau K.F., Garcia-Barcelo M., Waye M.M., Lovestone S., Miller C.C., Anderton B.H. (1998). Isolation and chromosomal mapping of human glycogen synthase kinase-3 alpha and-3 beta encoding genes. Genome, 41, 720-727.
119. Hansen L., Arden K.C., Rasmussen S.B., Viars C.S., Vestergaard H., Hansen T., Moller A.M., Woodgett J.R., Pedersen O. (1997). Chromosomal mapping and mutational analysis of the coding region of the glycogen synthase kinase-3alpha and beta isoforms in patients with NIDDM. Diabetologia, 40, 940-946.
120. Badenhop R.F., Moses M.J., Scimone A., Mitchell P.B., Ewen-White K.R., Rosso A., Donald J.A., Adams L.J., Schofield P.R. (2002). A genome screen of 13 bipolar affective disorder pedigrees provides evidence for susceptibility loci on chromosome 3 as well as chromosomes 9, 13 and 19. Mol. Psychiat., 7, 851-859.
121. Lander E., Kruglyak L. (1995). Genetic dissection of complex traits: Guidelines for interpreting and reporting linkage results. Nat. Genet., 11, 241-247.
122. Russ C., Lovestone S., Powell J.F. (2001). Identification of sequence variants and analysis of the role of the glycogen synthase kinase 3 beta gene and promoter in late onset Alzheimer's disease. Mol. Psychiat., 6, 320-324.
123. Tubazio V., Benedetti F., Serretti A., Plioa C., Pirovano A., Smeraldi E. (2004). Glycogen synthase kinase (GSK) gene promoter polymorphism: a TDT and haplotype approach in mood disorders. Am. J. Med. Genet., 130B, P1.24.
124. Gottesman I.I., Gould T.D. (2003). The endophenotype concept in psychiatry: Etymology and strategic intentions. Am. J. Psychiat., 160, 636-645.
125. Benedetti F., Serretti A., Colombo C., Lorenzi C., Tubazio V., Smeraldi E. (2004). A glycogen synthase kinase 3-beta promoter gene single nucleotide polymorphism is associated with age at onset and response to total sleep deprivation in bipolar depression. Neurosci. Lett., 368, 123-126.
126. Benedetti F., Serretti A., Pontiggia A., Bernasconi A., Lorenzi C., Colombo C., Smeraldi E. (2005). Long-term response to lithium salts in bipolar illness is influenced by the glycogen synthase kinase 3-beta-50 T/C SNP. Neurosci. Lett., 376, 51-55.
127. Benedetti F., Bernasconi A., Lorenzi C., Pontiggia A., Serretti A., Colombo C., Smeraldi E. (2004). A single nucleotide polymorphism in glycogen synthase kinase 3-beta promoter gene influences onset of illness in patients affected by bipolar disorder. Neurosci. Lett., 355, 37-40.
128. Einat H., Manji H.K., Belmaker R.H. (2003). New approaches to modeling bipolar disorder. Psychopharmacol. Bull., 37, 47-63.
129. Lamberty Y., Margineanu D.G., Klitgaard H. (2001). Effect of the new antiepileptic drug levetiracetam in an animal model of mania. Epilepsy Behav., 2, 454-459.
130. van Kammen D.P., Docherty J.P., Marder S.R., Rosenblatt J.E., Bunney W.E. Jr. (1985). Lithium attenuates the activation-euphoria but not the psychosis induced by d-amphetamine in schizophrenia. Psychopharmacology (Berlin), 87, 111-115.
131. Van Kammen D.P., Murphy D.L. (1975). Attenuation of the euphoriant and activating effects of d-and l-amphetamine by lithium carbonate treatment. Psychopharmacologia, 44, 215-224.
132. Huey L.Y., Janowsky D.S., Judd L.L., Abrams A., Parker D., Clopton P. (1981). Effects of lithium carbonate on methylphenidate-induced mood, behavior, and cognitive processes. Psychopharmacology (Berlin), 73, 161-164.
133. Beaulieu J.M., Sotnikova T.D., Yao W.D., Kockeritz L., Woodgett J.R., Gainetdinov R.R., Caron M.G. (2004). Lithium antagonizes dopaminedependent behaviors mediated by an AKT/glycogen synthase kinase 3 signaling cascade. Proc. Natl. Acad. Sci. USA, 101, 5099-5104.
134. Gould T.D., Einat H., Bhat R., Manji H.K. (2004). AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol.1-4.
135. Porsolt R.D., Le Pichon M., Jalfre M. (1977). Depression: A new animal model sensitive to antidepressant treatments. Nature, 266, 730-732.
136. Kaidanovich-Beilin O., Milman A., Weizman A., Pick C.G., Eldar-Finkelman H. (2004). Rapid antidepressive-like activity of specific glycogen synthase kinase-3 inhibitor and its effect on beta-catenin in mouse hippocampus. Biol. Psychiat., 55, 781-784.
137. Kroczka B., Branski P., Palucha A., Pilc A., Nowak G. (2001). Antidepressantlike properties of zinc in rodent forced swim test. Brain Res. Bull., 55, 297-300.
138. Nowak G., Szewczyk B., Wieronska J.M., Branski P., Palucha A., Pilc A., Sadlik K., Piekoszewski W. (2003). Antidepressant-like effects of acute and chronic treatment with zinc in forced swim test and olfactory bulbectomy model in rats. Brain Res. Bull., 61, 159-164.
139. Kroczka B., Zieba A., Dudek D., Pilc A., Nowak G. (2000). Zinc exhibits an antidepressant-like effect in the forced swimming test in mice. Pol. J. Pharmacol., 52, 403-406.
140. Szewczyk B., Branski P., Wieronska J.M., Palucha A., Pilc A., Nowak G. (2002). Interaction of zinc with antidepressants in the forced swimming test in mice. Pol. J. Pharmacol., 54, 681-685.
141. Wyska E., Szymura-Oleksiak J., Opoka W., Bas B., Niewiara E., Pomierny L., Dybala M., Nowak G. (2004). Pharmacokinetic interaction after joint administration of zinc and imipramine in forced swim test in mice. Pol. J. Pharmacol., 56, 479-484.
142. Nowak G., Siwek M., Dudek D., Zieba A., Pilc A. (2003). Effect of zinc supplementation on antidepressant therapy in unipolar depression: A preliminary placebo-controlled study. Pol. J. Pharmacol., 55, 1143-1147.
143. Frederickson C.J., Koh J.Y., Bush A.I. (2005). The neurobiology of zinc in health and disease. Nat. Rev. Neurosci., 6, 449-462.
144. Gould T.D., Manji H.K. (2005). Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology, 30, 1223-1237.
145. Eldar-Finkelman H. (2002). Glycogen synthase kinase 3: An emerging therapeutic target. Trends Mol. Med., 8, 126-132.
146. Cohen P., Goedert M. (2004). GSK-3 inhibitors: Development and therapeutic potential. Nat. Rev. Drug. Discov., 3, 479-487.
147. Martinez A., Castro A., Dorronsoro I., Alonso M. (2002). Glycogen synthase kinase 3 (GSK-3) inhibitors as new promising drugs for diabetes, neurodegeneration, cancer, and inflammation. Med. Res. Rev., 22, 373-384.
148. Bhat R.V., Xue Y., Berg S., Hellberg S., Ormo M., Nilsson Y., Radesater A.C., Jerning E., Markgren P.O., Borgegard T., Nylof M., Gimenez-Cassina A., Hernandez F., Lucas J.J., Díaz-Nido J., Avila J. (2003). Structural insights and biological effects of glycogen synthase kinase 3 specific inhibitor AR-A014418. J. Biol. Chem., 278, 45937-45945.
149. Martínez A., Alonso M., Castro A., Perez C., Moreno F.J. (2002). First non-ATP competitive glycogen synthase kinase 3 beta (GSK-3beta) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer's disease. J. Med. Chem., 45, 1292-1299.
150. Plotkin B., Kaidanovich O., Talior I., Eldar-Finkelman H. (2003). Insulin mimetic action of synthetic phosphorylated peptide inhibitors of glycogen synthase kinase-3. J Pharmacol. Exp. Ther., 305, 974-980.
151. Gould T.D., Zarate C.A., Manji H.K. (2004). Glycogen synthase kinase-3: A target for novel bipolar disorder treatments. J. Clin. Psychiat., 65, 10-21.
152. Hasler G., Drevets W.C., Manji H.K., Charney D.S. (2004). Discovering endophenotypes for major depression. Neuropsychopharmacology, 29, 1765-1781.
153. Gould T.D., Manji, H.K. (2005). Glycogen synthase kinase-3: A putative molecular target for lithium mimetic drugs. Neuropsychopharmacology (in press).
154. Alimohamad H., Rajakumar N., Seah Y.H., Rushlow W. (in press). Antipsychotics alter the protein expression levels of b-catenin and GSK-3 in the rat medial prefrontal cortex and striatum. Biol. Psychiat.
155. Svenningsson P., Tzavara E.T., Carruthers R., Rachleff I., Wattler S., Nehls M., McKinzie D.L., Fienberg A.A., Nomikos G.G., Greengard P. (2003). Diverse psychotomimetics act through a common signaling pathway. Science, 302, 1412-1415.
156. Gould T.D., Einat H., Bhat R., Manji H.K. (2004). AR-A014418, a selective GSK-3 inhibitor, produces antidepressant-like effects in the forced swim test. Int. J. Neuropsychopharmacol., 1-4.
157. Phiel C.J., Wilson C.A., Lee V.M., Klein P.S. (2003). GSK-3alpha regulates production of Alzheimer's disease amyloid-beta peptides. Nature, 423, 435-439.
158. Perez M., Hernandez F., Lim F., Díaz-Nido J., Avila J. (2003). Chronic lithium treatment decreases mutant tau protein aggregation in a transgenic mouse model. J. Alzheimers Dis., 5, 301-308.
159. Su Y., Ryder J., Li B., Wu X., Fox N., Solenberg P., Brune K., Paul S., Zhou Y., Liu F., Ni B. (2004). Lithium, a common drug for bipolar disorder treatment, regulates amyloid-beta precursor protein processing. Biochemistry, 43, 6899-6908.